Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gold Glyconanoparticles Combined with 91-99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder Tumors.
Terán-Navarro H, Zeoli A, Salines-Cuevas D, Marradi M, Montoya N, Gonzalez-Lopez E, Ocejo-Vinyals JG, Dominguez-Esteban M, Gutierrez-Baños JL, Campos-Juanatey F, Yañez-Diaz S, Garcia-Castaño A, Rivera F, Duran I, Alvarez-Dominguez C. Terán-Navarro H, et al. Among authors: duran i. Cancers (Basel). 2022 May 13;14(10):2413. doi: 10.3390/cancers14102413. Cancers (Basel). 2022. PMID: 35626016 Free PMC article.
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma.
Mar N, Zakharia Y, Falcon A, Morales-Barrera R, Mellado B, Duran I, Oh DY, Williamson SK, Gajate P, Arkenau HT, Jones RJ, Teo MY, Turan T, McLaughlin RT, Peltier HM, Chong E, Atluri H, Dean JP, Castellano D. Mar N, et al. Among authors: duran i. Cancers (Basel). 2023 May 30;15(11):2978. doi: 10.3390/cancers15112978. Cancers (Basel). 2023. PMID: 37296940 Free PMC article.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Among authors: duran i. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Powles T, et al. Among authors: duran i. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12. N Engl J Med. 2021. PMID: 33577729 Free PMC article. Clinical Trial.
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain.
Guillem Porta V, Camps C, Climent Durán MÁ, Gallardo E, González Del Alba A, Lázaro-Quintela M, Méndez Vidal MJ, Pinto Marín Á, Puente J, Antón-Rodríguez C, Caballero-Martínez F, Campos-Lucas FJ, Lugo I, Rogado Á, Durán I. Guillem Porta V, et al. Among authors: duran i. Clin Transl Oncol. 2022 Mar;24(3):495-502. doi: 10.1007/s12094-021-02703-9. Epub 2021 Sep 5. Clin Transl Oncol. 2022. PMID: 34482526
Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer.
Malapelle U, Pisapia P, Addeo A, Arrieta O, Bellosillo B, Cardona AF, Cristofanilli M, De Miguel-Perez D, Denninghoff V, Durán I, Jantus-Lewintre E, Nuzzo PV, O'Byrne K, Pauwels P, Pickering EM, Raez LE, Russo A, Serrano MJ, Gandara DR, Troncone G, Rolfo C. Malapelle U, et al. Among authors: duran i. Expert Rev Mol Diagn. 2021 Nov;21(11):1165-1178. doi: 10.1080/14737159.2021.1985468. Epub 2021 Oct 11. Expert Rev Mol Diagn. 2021. PMID: 34570988 Review.
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Schmidinger M, Motzer RJ, Rolland F, Staehler M, Rink M, Retz M, Csoszi T, McCaffrey JA, De Giorgi U, Caserta C, Duran I, Benzaghou F, Clary DO, Albiges L, Choueiri TK, Tannir NM. Schmidinger M, et al. Among authors: duran i. Acta Oncol. 2022 Jan;61(1):52-57. doi: 10.1080/0284186X.2021.1995041. Epub 2021 Nov 4. Acta Oncol. 2022. PMID: 34736367 Free PMC article. Clinical Trial.
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group. Siefker-Radtke AO, et al. Among authors: duran i. Lancet Oncol. 2022 Feb;23(2):248-258. doi: 10.1016/S1470-2045(21)00660-4. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030333 Clinical Trial.
376 results